Tarek A. Leil
YOU?
Author Swipe
View article: Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients
Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients Open
Edoxaban is an orally active inhibitor of activated factor X (FXa). Population pharmacokinetic (PK) and pharmacodynamic (PD) analyses were performed to characterize the PK and PK–PD relationships of edoxaban in pediatric patients to identi…
View article: Representation of antibodies is key to generate a predictive vaccine quantitative systems pharmacology (QSP) model
Representation of antibodies is key to generate a predictive vaccine quantitative systems pharmacology (QSP) model Open
View article: Supplementary Figure 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Supplementary Figure 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Supplementary Figure 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
View article: Supplementary Figure 2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Supplementary Figure 2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Supplementary Figure 2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
View article: Data from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Data from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Folylpolyglutamate synthase (FPGS) catalyzes the polyglutamation of folic acid, methotrexate, and pemetrexed to produce highly active metabolites. To characterize genetic variation in the FPGS gene, FPGS, have resequenced the gene i…
View article: Supplementary Legends 1-2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Supplementary Legends 1-2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Supplementary Legends 1-2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
View article: Data from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Data from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Folylpolyglutamate synthase (FPGS) catalyzes the polyglutamation of folic acid, methotrexate, and pemetrexed to produce highly active metabolites. To characterize genetic variation in the FPGS gene, FPGS, have resequenced the gene i…
View article: Supplementary Table 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Supplementary Table 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Supplementary Table 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
View article: Supplementary Figure 2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Supplementary Figure 2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Supplementary Figure 2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
View article: Supplementary Legends 1-2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Supplementary Legends 1-2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Supplementary Legends 1-2 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
View article: Supplementary Table 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Supplementary Table 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Supplementary Table 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
View article: Supplementary Figure 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
Supplementary Figure 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Open
Supplementary Figure 1 from Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene
View article: Virtual Populations for Quantitative Systems Pharmacology Models
Virtual Populations for Quantitative Systems Pharmacology Models Open
Quantitative systems pharmacology (QSP) places an emphasis on dynamic systems modeling, incorporating considerations from systems biology modeling and pharmacodynamics. The goal of QSP is often to quantitatively predict the effects of clin…
View article: Virtual Populations for Quantitative Systems Pharmacology Models
Virtual Populations for Quantitative Systems Pharmacology Models Open
Quantitative systems pharmacology (QSP) places an emphasis on dynamic systems modeling, incorporating considerations from systems biology modeling and pharmacodynamics. The goal of QSP is often to quantitatively predict the effects of clin…
View article: Model‐Based Meta‐Analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development
Model‐Based Meta‐Analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development Open
A nonlinear mixed effects modeling approach was used to conduct a model‐based meta‐analysis (MBMA) of longitudinal, summary‐level, baseline‐corrected 28‐joint Disease Activity Score (ΔDAS28) clinical trial data from seven approved rheumato…
View article: Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing
Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing Open
BMS‐986184 is a human, second‐generation, anti–interferon‐γ–induced protein 10 (IP‐10) monoclonal antibody. In this study the pharmacokinetics and target engagement (TE) of BMS‐986184 in healthy participants were characterized using popula…
View article: Review of Quantitative Systems Pharmacological Modeling in Thrombosis
Review of Quantitative Systems Pharmacological Modeling in Thrombosis Open
Hemostasis and thrombosis are often thought as two sides of the same clotting mechanism whereas hemostasis is a natural protective mechanism to prevent bleeding and thrombosis is a blood clot abnormally formulated inside a blood vessel, bl…
View article: Antibodies to Modulate Surface Receptor Systems Are Often Bivalent and Must Compete in a Two‐Dimensional Cell Contact Region
Antibodies to Modulate Surface Receptor Systems Are Often Bivalent and Must Compete in a Two‐Dimensional Cell Contact Region Open
Mechanistic models have been developed to calibrate to and predict pharmacodynamic (PD) responses for therapeutic antibodies that modulate cell surface molecules. To accurately reflect in vivo antibody–receptor interactions and predict rec…
View article: A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins Open
Immunogenicity is a major challenge in drug development and patient care. Currently, most efforts are dedicated to the elimination of the unwanted immune responses through T-cell epitope prediction and protein engineering. However, because…
View article: Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1
Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1 Open
View article: Review of quantitative systems pharmacological modeling in thrombosis
Review of quantitative systems pharmacological modeling in thrombosis Open
Hemostasis and thrombosis are often thought as two sides of the same clotting mechanism whereas hemostasis is a natural protective mechanism to prevent bleeding and thrombosis is a blood clot abnormally formulated inside a blood vessel, bl…
View article: Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation Open
This analysis describes the population pharmacokinetics ( PPK ) of apixaban in nonvalvular atrial fibrillation ( NVAF ) subjects, and quantifies the impact of intrinsic and extrinsic factors on exposure. The PPK model was developed using d…
View article: QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models
QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models Open
Quantitative systems pharmacology (QSP) modeling has become increasingly important in pharmaceutical research and development, and is a powerful tool to gain mechanistic insights into the complex dynamics of biological systems in response …
View article: Investigating Transporter‐Mediated Drug‐Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin
Investigating Transporter‐Mediated Drug‐Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin Open
Rosuvastatin is a frequently used probe in transporter‐mediated drug‐drug interaction (DDI) studies. This report describes the development of a physiologically based pharmacokinetic (PBPK) model of rosuvastatin for prediction of pharmacoki…
View article: Editorial: The emerging discipline of quantitative systems pharmacology
Editorial: The emerging discipline of quantitative systems pharmacology Open
EDITORIAL article Front. Pharmacol., 30 June 2015Sec. Experimental Pharmacology and Drug Discovery Volume 6 - 2015 | https://doi.org/10.3389/fphar.2015.00129